Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC

STATUS

Recruiting
End date

Jun 29, 2026
participants needed

522
sponsor

The Clatterbridge Cancer Centre NHS Foundation Trust

Send

Updated on 19 February 2024

See if I qualify

diabetes

platelet count

neutrophil count

nivolumab

liver transplant

carcinoma

hypothyroidism

type 1 diabetes mellitus

renal function test

hepatocellular carcinoma

TACE

vitiligo

hair thinning

Summary

This study evaluates the addition of nivolumab to TACE/TAE in the treatment of patients with intermediate stage hepatocellular carcinoma. All patients will receive TACE/TAE and half will receive nivolumab.

Description

A significant proportion of HCC patients present with, or progress to, intermediate stage disease and these patients are typically treated with transarterial chemo-embolisation (TACE) or transarterial embolisation (TAE).

However, since TACE/TAE is generally a palliative therapy, it provides a potential backbone for the addition of effective systemic therapies with the aim of improving survival outcomes. Since TACE may liberate an abundance of tumour antigens and 'danger' signals, it may lend itself to combination with immunotherapeutic strategies.

Nivolumab is a human monoclonal antibody. Nivolumab targets the programmed death-1 PD-1) cluster of differentiation 279 (CD279) cell surface membrane receptor. PD-1 is a negative regulatory molecule expressed by activated T and B lymphocytes.

Details

Condition	Adenocarcinoma, Adenocarcinoma, HEPATIC NEOPLASM, HEPATOCELLULAR CARCINOMA
Age	16-100 years
Treatment	Nivolumab and TACE/TAE, TACE/TAE
Clinical Study Identifier	NCT04268888
Sponsor	The Clatterbridge Cancer Centre NHS Foundation Trust
Last Modified on	19 February 2024

How understandable was the trial content above?

Hard to understand

Easy to understand

Eligibility		Yes	No	Not Sure
Inclusion Criteria
	Histological diagnosis of HCC and at least one uni-dimensional lesion measurable according to RECIST 1.1 criteria by CT-scan or MRI
	Not a candidate for surgical resection or liver transplantation
	Aged 16 years and estimated life expectancy >3 months
	ECOG performance status 0-1
	Adequate haematological function
	Hb 9g/L
	Absolute neutrophil count 1.0x109/L
	Platelet count 60x109/L
	Bilirubin 50 mol/L, AST,ALT and ALP 5 x ULN
	Adequate renal function; Creatinine 1.5ULN (Using Cockcroft-Gault Formula)
	INR 1.6
	Child-Pugh A (score 6) (Appendix D)
	HAP score A, B or C (Appendix E)
	No contra-indications to T-cell checkpoint inhibitor therapy (use of immunosuppressive drugs including steroids at dose equivalent to prednisolone >10mg/day unless used as replacement therapy; organ transplantation; subjects with an active, known or suspected autoimmune disease. Subjects with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, lichen planus or other conditions not expected to recur in the absence of an external trigger are permitted to enrol)
	Women of child-bearing potential should have a negative pregnancy test prior to study entry. Both men and women must be using an adequate contraception method, which must be continued for 5 months after completion of treatment for women and 7 months for men
	Written informed consent
Exclusion Criteria
	Extrahepatic metastasis
	Prior embolisation, systemic or radiation therapy for HCC
	Any contraindications for hepatic embolisation procedures including portosystemic shunt, hepatofugal blood flow, known severe atheromatosis
	Investigational therapy or major surgery within 4 weeks of trial entry
	History of variceal bleeding within the past 4 weeks
	Child-Pugh cirrhosis B or C (score 7)
	HAP score D
	Hepatic encephalopathy
	Ascites refractory to diuretic therapy
	Documented occlusion of the hepatic artery or main portal vein5
	Hypersensitivity to intravenous contrast agents
	Active clinically serious infection > Grade 2 NCI-CTC
	Pregnant or lactating women
	Known history of HIV infection
	HBV chronic infection with HBV DNA > 500IU/mL or without antiviral therapy; HBV patients with cirrhosis should be treated
	History of second malignancy except those treated with curative intent more than three years previously without relapse and non-melanotic skin cancer or cervical carcinoma in situ 18. Evidence of severe or uncontrolled systemic disease, or laboratory finding that in the view of the Investigator makes it undesirable for the patient to participate in the trial 19. Psychiatric or other disorder likely to impact on informed consent 20. Patient is unable and/or unwilling to comply with treatment and study instructions 20. Interstitial lung disease that is symptomatic or may interfere with the detection or management of suspected treatment-related pulmonary toxicity
	Evidence of uncontrolled, active infection, requiring parenteral anti-bacterial, anti-viral or antifungal therapy within 7 days prior to administration of study medication
	Positive test for latent TB or evidence of active TB
	Hypersensitivity to any of the active substances or excipients
	Patients who have received a live vaccine within 30 days prior to the first dose of trial treatment
	Subjects with a condition requiring systemic treatment with either corticosteroids (> 10 mg daily prednisone equivalent) or other immunosuppressive medications within 14 days of the first dose of study drug administration
	Any uncontrolled inflammatory GI disease including Crohn's Disease and ulcerative colitis
	Participants with an active, known or suspected autoimmune disease. Participants with type I diabetes mellitus, hypothyroidism only requiring hormone replacement, skin disorders (such as vitiligo, psoriasis, or alopecia) not requiring systemic treatment, or conditions not expected to recur in the absence of an external trigger are permitted to enrol

How to participate?

Step 1 Connect with a study center

Select a site
Send a message

You have contacted , on

Your message has been sent to the study team at ,

A copy of the message has been sent to your email

What happens next?

You can expect the study team to contact you via email or phone in the next few days.
Sign up as volunteer to help accelerate the development of new treatments and to get notified about similar trials.

You are contacting

Primary Contact

By sending a message, I agree that my data will be sent to a representative for the selected site and processed in accordance with this website's Privacy Policy (see link in footer).

Step 2 Get screened

Additional screening procedures may be conducted by the study team before you can be confirmed eligible to participate.

Learn more

Step 3 Enroll in the clinical study

If you are confirmed eligible after full screening, you will be required to understand and sign the informed consent if you decide to enroll in the study. Once enrolled you may be asked to make scheduled visits over a period of time.

Learn more

Step 4 Get your study results

Complete your scheduled study participation activities and then you are done. You may receive summary of study results if provided by the sponsor.

Learn more

Similar trials to consider

Browse trials for

type 1 diabetes mellitus

renal function test

hepatocellular carcinoma

TACE

vitiligo

hair thinning

Not finding what you're looking for?

Every year hundreds of thousands of volunteers step forward to participate in research. Sign up as a volunteer and receive email notifications when clinical trials are posted in the medical category of interest to you.

Study Definition

Wikipedia

Nivolumab in Combination With TACE/TAE for Patients With Intermediate Stage HCC